|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #redirect:[[ |
| {{SI}}
| |
| {{CMG}}
| |
|
| |
|
| {{SK}} Respiratory distress syndrome; surfactant deficient disease
| | Neonatal respiratory distress syndrome]] |
| | |
| ==Overview==
| |
| | |
| Hyaline membrane disease is the most common cause of death in newborns. It results from inability of premature type II pneumocytes to make surfactant. Surfactant reduces surface tension. Alveoli collapse when surfactant is not present
| |
| | |
| ==Diagnosis==
| |
| | |
| Imaging findings are
| |
| | |
| * Low lung volumes
| |
| * Bilateral granular opacities (represent areas of collapsed alveoli mixed with areas of open alveoli)
| |
| | |
| <gallery>
| |
| Image:
| |
| | |
| Hylaine membrane disease 001.jpg
| |
| | |
| Image:
| |
| | |
| Hylaine membrane disease 002.jpg|Post surfactant treatment
| |
| | |
| | |
| </gallery>
| |
| ==Treatment==
| |
| | |
| Treatment may be achieved through the administration of surfactant
| |
| | |
| * Pros:
| |
| | |
| ** Decreased oxygen and ventilator requirements
| |
| ** Decreased airblock complications
| |
| ** Deceased intracranial hemorrhage
| |
| | |
| * Cons:
| |
| | |
| **Increased Patent Ductus arteriosus.
| |
| ** Increased pulmonary hemorrhage.
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{WH}}
| |
| {{WS}}
| |
Revision as of 15:33, 3 August 2012
- redirect:[[
Neonatal respiratory distress syndrome]]